Skip to content
Contact us
HI campaign_landing page header_Sep2023_v2

Health equity is crucial to ensuring that all individuals have access to essential care. The COVID-19 pandemic demonstrated how some groups, such as Black, Asian, and minority ethnic (BAME) communities, and those living in deprived areas, were disproportionately affected by the virus. However, while COVID-19 drew attention to these healthcare disparities, they have existed for decades.

In recent times, regulatory bodies have put tackling health inequities at the front line of their agendas, recognizing the crucial role real-world data (RWD) play in answering the questions that help us understand and reverse current and future health inequity, and expanding the reach of new technologies to underserved patient populations.

At CorEvitas, part of Thermo Fisher Scientific, we are committed to working hand in hand with our partners to generate high-quality, fit-for-purpose real-world evidence (RWE) that not only recognizes and accounts for health inequities in development and assessment, but also quantifies its impact on healthcare outcomes. Together, we can create a more equitable healthcare system that ensures access to essential care and a deeper understanding of the many factors associated with the costs of disease for all individuals, regardless of their background or circumstances.

Our work supporting health equity  

HI item image heart

Impact of gender, ethnicity, and social deprivation on access to surgical or transcatheter AVR in aortic stenosis: A Retrospective Database Study in England

A retrospective database study in England that assessed gender, ethnicity, and deprivation-based differences in provision of aortic valve replacement (AVR) for adults with aortic stenosis (AS).

Read the article
HI item image eye

In our sights

 

In this article, Dr Caoimhe Rice explores the future of retinal healthcare, and explores how to ensure it incorporates healthy equity.

Read the article
HI item image femail reproductive

Differences in inequalities of uterine cancer treatment before and after COVID-19 in England

Dr Jennifer Davidson assesses the changes in uterine cancer treatment before and after the emergence of COVID-19.

View the poster and abstract
HI item image breast cancer

Supporting an Integrated Care System to reduce inequalities within breast cancer

Our case study examines how we supported an ICS to reduce inequalities within breast cancer, using the Health Inequality Dashboard, part of the Vantage® RWE Platform.

View the case study
HI item image psoriasis

Outcomes of Biologic Use in Asian Compared with Non-Hispanic White Adult Psoriasis Patients from the CorEvitas Psoriasis Registry

This study compared the 6-month effectiveness of biologic therapy between Asian and white plaque patients with psoriasis in the CorEvitas Psoriasis Registry.

Read the manuscript
HI item image diabetes

WHITEPAPER: Utilizing RWD to uncover health inequalities in type 2 diabetes

Utilizing  CorEvitas' Vantage® RWE platform, our whitepaper demonstrates how inequalities can be identified in type 2 diabetes using the English Hospital Episode Statistics (HES) dataset and measuring HCRU in terms of hospital admissions.

Download the white paper
HI item image study

Improving diversity in study participation: Patient perspectives on barriers, racial differences, and the role of communities

Qualitative research was conducted to identify the potential motivators and barriers to study participation across different races and ethnicities-- preferred delivery of education and information to support healthcare decision-making and the role of the community.

Read the study
HI item image psoriasis

Racial/ethnic differences in biologic treatment patterns among patients in the CorEvitas Psoriasis Registry

This study assesses biologic discontinuation and switching rates after six months of therapy among psoriasis patients of different racial/ethnic backgrounds in the CorEvitas US/Canadian Psoriasis Registry.

View the poster
HI item image psoriasis

Similar response to biologic therapy across racial and ethnic groups among patients with psoriasis enrolled in the CorEvitas Psoriasis Registry

This study uses data from the CorEvitas Psoriasis Registry, an observational cohort of patients evaluated in dermatology clinics, to better understand the response to biologics across racial/ethnic groups.

Read the study
HI item image atopic dermatitis

Racial and Ethnic Differences in Sociodemographic and Treatment Characteristics Among Patients With Atopic Dermatitis in the United States

We compared differences in AD disease and treatment characteristics (including systemic treatments) among self-reported racial/ethnic groups in real-world AD patients who are candidates for, or currently on, systemic therapy.

View the poster
HI item image sickle cell

Societal Burden of Sickle Cell Disease in the UK: Empirical estimates of productivity loss and loss of future income using real-world evidence

We estimate productivity loss and loss of future income utilizing RWE: the English Clinical Practice Research Datalink (CPRD) linked with Hospital Episode Statistics (HES), and mortality data from the Office of National Statistics (ONS) death register.

Read the abstract
HI item image RA

Disparities in Burden of Disease in Patients with Rheumatoid Arthritis Across Racial and Ethnic Groups

Using data from CorEvitas' Rheumatoid Arthritis registry, this study examines differences in disease burden and change in clinical outcomes over time across racial and ethnic groups.

Read the abstract
HI item image psoriasis

The propensity to receive a HSCT in DLBCL patients based on sex, ethnicity and deprivation

Utilizing linked real-world datasets, we estimate the odds of receiving a HSCT among a representative cohort of DLBCL patients in England. 

View the poster
HI item image psoriasis

A demographic description of women with uncomplicated urinary tract infection in England: a primary care electronic health record and notes review

This poster describes the age, ethnicity, and treatment of women with uncomplicated urinary tract infections (uUTIs) using electronic health records (EHR) and a notes review for patients from a large primary care network, covering 32 practices in southeast England.

View the poster
HI item image RA

Disparities in Burden of Disease in Patients with Rheumatoid Arthritis Across Racial and Ethnic Groups

Using data from CorEvitas' Rheumatoid Arthritis registry, this article examines differences in disease burden and change in clinical outcomes over time across racial and ethnic groups.

Read the article

IDE is embedded in every CorEvitas RWE solution. And it starts with our people. 

We have taken many steps to ensure that inclusion, diversity, and equity are embedded into who we are and how we do business, both internally and externally.

HI IDE image

Stunning, visual real-world data storytelling

The Health Inequalities Dashboard, part of CorEvitas' Vantage® RWD platform, interrogates Hospital Episode Statistics (HES) data to provide powerful analyses of patient cohorts in England.

The dashboard’s rigorous health inequality analysis helps you quantify health inequalities for a specific disease, identify the groups disproportionately affected, and understand local challenges. Request a demo today to find out how we can help you support your national and local healthcare stakeholders in providing quality, evidence-based care equal to the patient populations they serve.

HI campaign
  • Quantify health inequalities for a specific disease
  • Understand the local challenges
  • Identify the groups disproportionately affected
  • Support HCPs in understanding health inequality
  • Help support the delivery of quality, evidence-based care

How can we help you?

Our gold-standard RWE solutions provide the life sciences industry with the objective data and clinical insights needed to bring safe, effective treatments to market. 

With over 150 epidemiologists, statisticians, and pharmacovigilance experts on staff and 20 years of experience in syndicated longitudinal registries, CorEvitas is expertly placed to provide the scientific guidance that helps support even the most complex evidence generation.

Talk with our team to discover how we can tailor a solution to meet your unique needs - from discovery through post-market. 

Contact our team